MAGE-D2 siRNA (h): sc-62581



The Power to Question

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens that are expressed in tumors of different histologic types and in normal testis and placenta. MAGE-D2 (melanoma-associated antigen D2), also known as BCG1 (breast cancer-associated gene 1), 11B6, HCA10 or JCL-1, is a 606 amino acid protein that contains one MAGE domain. Expressed throughout the body, MAGE-D2 is thought to function as a negative regulator of p53 (a potent tumor suppressor), possibly contributing to tumor formation and metastasis. Multiple isoforms of MAGE-D2 exist due to alternative splicing events.

REFERENCES

- Lucas, S., et al. 1999. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 59: 4100-4103.
- Langnaese, K., et al. 2001. Expression pattern and further characterization of human MAGE-D2 and identification of rodent orthologues. Cytogenet. Cell Genet. 94: 233-240.
- 3. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 300470. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/
- 4. Harper, R., et al. 2004. Identification of a novel MAGE-D2 antisense RNA transcript in human tissues. Biochem. Biophys. Res. Commun. 324: 199-204.
- 5. Bertrand, M., et al. 2004. Comparative expression analysis of the MAGED genes during embryogenesis and brain development. Dev. Dyn. 230: 325-334.
- Kidd, M., et al. 2006. The role of genetic markers—NAP1L1, MAGE-D2, and MTA1—in defining small-intestinal carcinoid neoplasia. Ann. Surg. Oncol. 13: 253-262.
- Papageorgio, C., et al. 2007. MAGE-D2: a novel p53-dissociator. Int. J. Oncol. 31: 1205-1211.

CHROMOSOMAL LOCATION

Genetic locus: MAGED2 (human) mapping to Xp11.21.

PRODUCT

MAGE-D2 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MAGE-D2 shRNA Plasmid (h): sc-62581-SH and MAGE-D2 shRNA (h) Lentiviral Particles: sc-62581-V as alternate gene silencing products.

For independent verification of MAGE-D2 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-62581A, sc-62581B and sc-62581C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MAGE-D2 siRNA (h) is recommended for the inhibition of MAGE-D2 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

MAGE-D2 (FW.6): sc-130443 is recommended as a control antibody for monitoring of MAGE-D2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MAGE-D2 gene expression knockdown using RT-PCR Primer: MAGE-D2 (h)-PR: sc-62581-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**